


FIG. 1


SAHA Patient: IV vs ORAL (200 mg/dose)



Best Available Copy


FIG. 2

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)



3/19


FIG. 3



Best Available Copy

4/19

FIG. 4




Best Available Copy

5/19


FIG. 5

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)



6/19

FIG. 6







FIG. 7

Protocol 01-021
(ORAL SAHA)
ARM A: SOLID
TUMOR PATIENTS
Cohort IIa (400 mg/dose)

8/19


FIG. 8



9/19


FIG. 9A

Oral 200 mg vs. 400 mg (Fasting)
Oral dose on Cycle 1 Day 8



10/19

FIG. 9B
Oral 200 mg vs. 400 mg (no-fasting)
Oral Dose on Cycle 1 Day 9



11/19

FIG. 9C
IV 200 mg vs. 400 mg
IV Dose on Cycle 1 Day 1




FIG. 10

Apparent Half-life of the Oral Dose
Half-life






FIG. 11
AUC of the Oral
Dose AUC_{last}



14/19



FIG. 12

Bioavailability after 200 and 400 mg by Day



15/19

MESOTHELIOMA



POST

FIG. 13

PRE

16/19






FIG. 14

A

B

Best Available Copy

17/19




B



A

FIG. 15

Best Available Copy



B


FIG. 16

A

Best Available Copy

2 Months Post SAHA

Pre-Therapy



A

FIG. 17

B

Best Available Copy